Working… Menu

Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02163720
Recruitment Status : Completed
First Posted : June 16, 2014
Last Update Posted : November 9, 2018
Information provided by (Responsible Party):

Brief Summary:
The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of trabectedin (Yondelis®)-Pegylated liposomal doxorubicin(Caelyx)®, in ovarian platinum sensitive cancer relapse.

Condition or disease Intervention/treatment
Ovarian Cancer Drug: Yondelis®-Caelyx®

Detailed Description:
Population : Patients aged 18 years and older with an epithelial ovarian cancer, fallopian tube or primary peritoneal with platinum-sensitive recurrent witch it was decided to initiate a treatment with trabectedin (Yondelis®)-Pegylated liposomal doxorubicin(Caelyx)®.

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 101 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 12 Months
Official Title: Non Interventional Study Dealing With the Use of Trabectedin (Yondelis®)-Pegylated Liposomal Doxorubicin (Caelyx®) in Patient With Platinum-sensitive Relapse
Actual Study Start Date : July 10, 2014
Actual Primary Completion Date : March 2017
Actual Study Completion Date : September 18, 2018

Group/Cohort Intervention/treatment
Yondelis®-Caelyx®-relapse ovarian cancer
Yondelis®-Caelyx®-relapse ovarian cancer
Drug: Yondelis®-Caelyx®
Observation of Yondelis®-Caelyx® administration
Other Name: Observation of Yondelis®-Caelyx® administration

Primary Outcome Measures :
  1. Evaluate the proportion of patient partially versus fully platinum-sensitive in relapse ovarian cancer [ Time Frame: Patient will be followed during 12 months ]
    To assess patient safety and the tolerance of Yondelis®-Caelyx® administered regarding the daily practice of the oncologist.

Secondary Outcome Measures :
  1. Choice of treatment [ Time Frame: at baseline ]
    Describe the reason why treatment by trabectedin and doxorubicine combination was initiated (ex : number of patients with previous intolerance to platinum as allergic reaction, residual peripherical neuropathy, alopecia; availability of the combination yondelis-caelyx in the treating site; number of sites where the yondelis-caelyx combination is the reference treatment)

  2. Characteristics of the population registered [ Time Frame: at baseline ]
    Describe the population that will be registered

  3. Evaluation of the modality of use of Yondelis®-Caelyx® [ Time Frame: during treatment (expected period = 6 months)-As it is an non interventionnal study, treatment period corresponds to the routine practice of each investigator ]
    Describe the way how treatment by Yondelis®-Caelyx® is administered in the daily practice for each patient (Initial dosage of caelyx and yondelis, number of cycles administered for each treatment , dose reductions occurence and reasons)

  4. Safety according to CTCAE v4.03 criteria [ Time Frame: Patient will be followed during 12 months ]
    To assess patient safety and the tolerance of Yondelis®-Caelyx® administered regarding the daily practice of the oncologist.

  5. Evaluation of clinical benefit [ Time Frame: baseline and during treatment (expected period of treatment = 6 months). As it is an non interventionnal study, treatment period corresponds to the routine practice of each investigator. ]

    Evaluation of clinical benefit will be performed during the physical examination at baseline and during the treatment

    At baseline : describe the number of patients how present the following related symptom disease : weight loss, ascites, abdominal pain, constipation, fatigue, occlusive syndrome

    Then, describe the number of patients how presented and improvement or a degradation of theses related symptom disease during the treatment

    Nota Bene : this cohort study is strictly observational and must represent the daily practice. No indications must be given regarding the frequency of the physical examination

  6. Efficacy of treatments [ Time Frame: during treatment and follow up period (maximum of 12 months) ]
    Evaluate the efficacy of Yondelis®-Caelyx® in terms of progression-free survival (PFS), Overall Survival (OS), response to treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with epithelial ovarian cancer, fallopian tube or peritoneal with treatment receiving in relapse platinum-sensitive

Inclusion Criteria:

  • Patients aged 18 years and over,
  • Patients with an epithelial ovarian cancer, fallopian tube or peritoneal who will receive Yondelis®-Caelyx® in relapse platinum-sensitive
  • Patients should be informed of the study orally and should not have any objection their data to be processed

Exclusion Criteria:

  • Patient participation in a clinical trial
  • Patient non-affiliated to a social security scheme.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02163720

Layout table for location information
Centre de Radiothérapie et d'Oncologie
Agen, France
Clinique de l'Europe
Amiens, France
ICO Paul Papin
Angers, France, 49100
Hôpital de la Côte Basque
Bayonne, France, 64100
Hôpital jean Minjoz
Besancon, France
Clinique Tivoli
Bordeaux, France
Hôpital Fleyriat
Bourg-En-Bresse, France
Hôpital Morvan - Centre Hospitalier Universitaire
Brest, France, 29200
Cabinet d'Oncologie - Hôpital Privé Sainte Marie
Chalon Sur Saone, France, 71100
Centre Hospitalier de Cholet
Cholet, France
Hôpital Privé Drôme Ardèche - Clinique Pasteur
Guilherand-granges, France, 07500
Hôpital Louis Pasteur
Le Coudray, France, 28630
Centre Oscar Lambret
Lille, France
Centre Hospitalier Universitaire Dupuytren
Limoges, France, 87042
CHU Dupuytren
Limoges, France
Centre Léon Bérard
Lyon, France, 69373
institut Paoli Calmette
Marseille, France
Centre Azuréen de Cancérologie
Mougins, France
Centre d'oncologie de Gentilly
Nancy, France
Centre Hospitalier Régional
Orléans, France
Hôpital Tenon
Paris, France, 75020
Hôpital de la Milétrie - Centre Hospitalier Universitaire de Poitiers - Pôle Régional de Cancérologie
Poitiers, France, 86021
Clinique Courlancy
Reims, France, 51100
Institut Jean Godinot
Reims, France
Clinique Armoricaine de Radiologie
Saint Brieuc, France
ICO Centre René Gauducheau
Saint Herblain, France, 44805
Clinique de l'Union
Saint Jean, France, 31240
Clinique de l'Alliance
Saint-cyr-sur-loire, France
GHPSO - Site Senlis
Senlis, France, 60309
Centre de Radiothérapie - Clinique Sainte-Anne
Strasbourg, France, 67000
Clinique Saint Jean
Toulon, France
Institut Claudius Regaud
Toulouse, France, 31059
Institut de Cancérologie Gustave Roussy
Villejuif, France, 94805
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Frédéric SELLE, MD Hôpital Tenon

Additional Information:

Layout table for additonal information
Responsible Party: ARCAGY/ GINECO GROUP Identifier: NCT02163720     History of Changes
Other Study ID Numbers: PROSPECTYON (GINECO-OV229)
First Posted: June 16, 2014    Key Record Dates
Last Update Posted: November 9, 2018
Last Verified: November 2018
Keywords provided by ARCAGY/ GINECO GROUP:
ovarian cancer
fallopian tube or primary peritoneal
Additional relevant MeSH terms:
Layout table for MeSH terms
Liposomal doxorubicin
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Disease Attributes
Pathologic Processes
Immune System Diseases
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Alkylating